Litcius/Paper detail

Lurbinectedin as second-line treatment for patients with small-cell lung cancer: a single-arm, open-label, phase 2 basket trial

José Trigo, Vivek Subbiah, Benjamin Besse, Víctor Moreno, Rafael López‐López, María Ángeles Sala, Solange Peters, Santiago Ponce, Cristian Fernández, Vicente Alfaro, Javier Gómez, Carmen Kahatt, Ali Zeaiter, Khalil Zaman, Valentina Boni, Jennifer Arrondeau, Maite Martínez, Jean‐Pierre Delord, Ahmad Awada, Rebecca Kristeleit, M.E. Olmedo, Luciano Wannesson, Javier Valdivia, María Jesús Rubio, Antonio Antón, John Sarantopoulos, Sant P. Chawla, Joaquín Mosquera, M. D’Arcangelo, Armando Santoro, Víctor M. Villalobos, Jacob Sands, Luis Paz‐Ares

2020The Lancet Oncology463 citationsDOI

Topics & Concepts

MedicineResponse Evaluation Criteria in Solid TumorsChemotherapyInternal medicineClinical trialOncologyProgressive diseaseLung cancerPhases of clinical researchDiscontinuationToxicitySurgeryLung Cancer Research StudiesLung Cancer Treatments and MutationsPARP inhibition in cancer therapy
Lurbinectedin as second-line treatment for patients with small-cell lung cancer: a single-arm, open-label, phase 2 basket trial | Litcius